Shanghai Kehua Bio-Engineering Co.,Ltd researches and develops, produces, and sells in vitro diagnostic products in China. The company offers HBV, hepatitis B, HCV antibody, alpha fetoprotein quantitative, and fecal occult blood test kits; carcino-embryonic antigen quantitative determination kits; test kits for antibody to treponema pallidum and human immunodeficiency virus, and the five serological markers of hepatitis B; and diagnostic kit for syphilis rapid plasma regain. It also provides automatic biochemical analysis systems for clinical laboratories and medical institutions; nucleic acid blood screening systems; automatic chemiluminescence measuring systems; microplate readers and plate washers; general and dedicated reagent packaging systems; and electrolyte analyzers. In addition, the company researches and develops diagnostic products in the field of renal disease that provides screening diagnosis and therapeutic effect monitoring solutions for patients with various types of kidney disease. Further, it offers single-part and multi-part nucleic acid detection, and enzyme immunoassay analysis systems; reagents for blood collection agencies and clinical diagnosis; and laboratory diagnostic instruments. Additionally, the company distributes automatic chemiluminescence, microbial, and blood and urine analysis systems, as well as their supporting supplies; and automatic biochemical analyzers and other products. It also establishes third-party medical laboratory centers; provides planning and designing, management consulting, equipment and reagent supplying, and supply chain optimization services for medical laboratories, as well as medical testing services. In addition, the company is involved in the social medical undertakings. It also exports its Kehua-branded products to 38 countries and regions. The company was founded in 1981 and is based in Shanghai, the People's Republic of China.
Shanghai Kehua Bio-Engineering Dividend Announcement
• Shanghai Kehua Bio-Engineering announced a annually dividend of ¥0.60 per ordinary share which will be made payable on 2023-05-10. Ex dividend date: 2023-05-10
• Shanghai Kehua Bio-Engineering annual dividend for 2023 was ¥0.60
• Shanghai Kehua Bio-Engineering's trailing twelve-month (TTM) dividend yield is -%
• Shanghai Kehua Bio-Engineering's payout ratio for the trailing twelve months (TTM) is -93.38%
• Shanghai Kehua Bio-Engineering's dividend growth over the last five years (2018-2023) was 55.97% year
• Shanghai Kehua Bio-Engineering's dividend growth over the last ten years (2013-2023) was 5.24% year
Shanghai Kehua Bio-Engineering Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2023-05-10 | ¥0.60 | annually | 2023-05-10 |
2022-07-19 | ¥0.07 | annually | 2022-07-19 |
2021-07-16 | ¥0.20 | annually | 2021-07-16 |
2020-07-09 | ¥0.07 | annually | 2020-07-09 |
2019-06-20 | ¥0.07 | annually | 2019-06-20 |
2018-05-25 | ¥0.07 | annually | 2018-05-25 |
2017-06-29 | ¥0.14 | annually | 2017-06-29 |
2016-06-29 | ¥0.12 | annually | |
2015-07-07 | ¥0.20 | annually | |
2014-04-23 | ¥0.23 | annually | |
2013-04-26 | ¥0.36 | annually | |
2012-04-24 | ¥0.40 | annually |
Shanghai Kehua Bio-Engineering Dividend per year
Shanghai Kehua Bio-Engineering Dividend growth
Shanghai Kehua Bio-Engineering Dividend Yield
Shanghai Kehua Bio-Engineering current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Shanghai Kehua Bio-Engineering stock? Use our calculator to estimate your expected dividend yield:
Shanghai Kehua Bio-Engineering Financial Ratios
Shanghai Kehua Bio-Engineering Dividend FAQ
Other factors to consider when evaluating Shanghai Kehua Bio-Engineering as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Shanghai Kehua Bio-Engineering stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Shanghai Kehua Bio-Engineering's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Shanghai Kehua Bio-Engineering publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Shanghai Kehua Bio-Engineering distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Shanghai Kehua Bio-Engineering are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Shanghai Kehua Bio-Engineering sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Shanghai Kehua Bio-Engineering distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Shanghai Kehua Bio-Engineering declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Shanghai Kehua Bio-Engineering's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Shanghai Kehua Bio-Engineering's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.